A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio

Posted by Shanthi Rexaline

Share on Facebook

Tweet on Twitter

Among the six coronavirus vaccine candidates that have entered human trials, two belong to publicly listed U.S. companies: Moderna Inc and Inovio Pharmaceuticals Inc Both stocks have rallied in reaction to updates on R&D and funding.

Moderna is up about 143% year-to-date and Inovio is higher by 265%.

Moderna, Inovio’s Vaccine Candidates

Both Moderna and Inovio use a modern approach as opposed to conventional vaccines that employ a weakened form of the pathogen, a killed pathogen or specific pieces of pathogen such as its protein, sugar or capsid.

Moderna is developing mRNA-1273, an mRNA vaccine, against the new coronavirus in collaboration with the Vaccine Research Center at the NIH’s National Institute of Allergy and Infectious Diseases. It is a vaccine against SARS-CoV-2 encoding for the spike, or S, protein….CLICK for complete article